Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA7 | P43166 | 6/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13969442 | 0.83 | TSHR (0.42) | ALDH1A1LMNAHSD17B10TSHRCA12 | |
| SCHEMBL24292366 | 0.79 | CHRM2 (0.40) | LMNATSHRALOX15 | |
| SCHEMBL896075 | 0.79 | CHRM3 (0.39) | ALDH1A1LMNATSHRCA12CA1 | |
| SCHEMBL24292367 | 0.78 | CHRM1 (0.46) | LMNATSHRMAPTSMN1; SMN2GAA | |
| SCHEMBL22877649 | 0.78 | SCN1A (0.36) | ALDH1A1LMNATSHRESR1HPGD | |
| SCHEMBL24292365 | 0.76 | CHRM2 (0.35) | ALDH1A1HPGD | |
| SCHEMBL10899341 | 0.75 | TDP1 (0.53) | ALDH1A1LMNATSHRCA12CA1 | |
| SCHEMBL10282953 | 0.75 | CHRNB2 (0.38) | ALDH1A1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL5114658 | 0.74 | CA12 (0.43) | ALDH1A1LMNAHSD17B10TSHRCA12 | |
| SCHEMBL20837014 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116999571-A | Antibody-drug conjugates comprising anti-B7-H3 antibodies | 尹图赛利有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| EP-4171655-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | Intocell, Inc. (KR) | 2023-05-03 | — | — | EP | disclosed |
| US-20220162190-A1 | BENZODIAZEPINE DERIVATIVES AND USES THEREOF | INTOCELL, INC. (KR) | 2022-05-26 | — | — | US | disclosed |
| US-20220047717-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | Y-Biologics Inc. (KR) | 2022-02-17 | — | — | US | disclosed |
| WO-2021260438-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | INTOCELL, INC. (KR) | 2021-12-30 | — | — | WO | disclosed |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2021-08-10 | — | — | US | disclosed |
| EP-3802546-A2 | NOVEL BENZODIAZEPINE DERIVATIVES AND USES THEREOF | Intocell, Inc. (KR) | 2021-04-14 | — | — | EP | disclosed |
| EP-2000150-B1 | TITANIUM OXIDE COMPLEX PARTICLE, DISPERSION SOLUTION OF THE PARTICLE, AND PROCESS FOR PRODUCTION OF THE PARTICLE | TOTO LTD (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150352227-A1 | METHOD FOR ACCUMULATING TITANIUM OXIDE COMPOSITE PARTICLES INTO A CANCER TISSUE | TOTO LTD (JP) | 2015-12-10 | — | — | US | disclosed |
| WO-2012166390-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20090130050-A1 | Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them | TOTO LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2000150-A9 | TITANIUM OXIDE COMPLEX PARTICLE, DISPERSION SOLUTION OF THE PARTICLE, AND PROCESS FOR PRODUCTION OF THE PARTICLE | Toto Ltd. (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20090018184-A1 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON | 2009-01-15 | — | — | US | disclosed |
| EP-2000150-A2 | TITANIUM OXIDE COMPLEX PARTICLE, DISPERSION SOLUTION OF THE PARTICLE, AND PROCESS FOR PRODUCTION OF THE PARTICLE | Toto Ltd. (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-7399782-B2 | Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) | 2008-07-15 | — | — | US | disclosed |
| US-20030199693-A1 | Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activies on PDE-5 phosphodiesterase | CHEN ING-JUN (TW) | 2003-10-23 | — | — | US | disclosed |
| US-6500853-B1 | ENZYME INHIBITORS SUCH AS 4-((1-BENZHYDRYL-5-(((BUTYLAMINO)-CARBONYL)AMINO)-1H-INDOL-3-YL)METHYL)-3 -METHOXYBENZOIC ACID USED AS ANTIINFLAMMATORY AGENTS FOR PROPHYLAXIS OF ARTHRITIS, INFLAMMATORY BOWEL DISEASE OR ASTHMA | GENETICS INSTITUTE, LLC | 2002-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | ALDH1A1 900/4885LMNA 726/4885HSD17B10 875/4885 |
| US-20220162190-A1 | BENZODIAZEPINE DERIVATIVES AND USES THEREOF | GABRB3, GABRB2, GABRB1 | ALDH1A1 900/4885LMNA 726/4885HSD17B10 875/4885 |
| US-20220047717-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | CD274, CD44, H1-3 | ALDH1A1 341/4885LMNA 3972/4885HSD17B10 2529/4885 |
| US-20090018184-A1 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases | CFTR, MUC1, SLC47A1 | ALDH1A1 3628/4885LMNA 2233/4885HSD17B10 3287/4885 |
| US-20030199693-A1 | Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activies on PDE-5 phosphodiesterase | PDE3A, PDE5A, PDE3B | ALDH1A1 3605/4885LMNA 1621/4885HSD17B10 3564/4885 |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | ALDH1A1 900/4885LMNA 726/4885HSD17B10 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.